[ad_1]
FRAMINGHAM, Mass. (PRWEB)
September 26, 2022
Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products is pleased to announce the appointment of Dr. Stuart Chaffee, a 20-year veteran in the biopharmaceutical industry, as Executive Chairman.
Dr. Chaffee brings a wealth of experience including contributing to starting four publicly traded biotechnology companies, raising over $900M in private and public capital, and $4.9B in transactions. In this new role for Olaris, Dr. Chaffee will partner with CEO Dr. Elizabeth O’Day and the Board of Directors to develop and execute strategic growth opportunities for the company.
“I am delighted and privileged to join the incredible team at Olaris at this exciting time,” said Dr. Chaffee. “Olaris’ pioneering metabolomic platform stands ready to deliver on its mission to dramatically improve our industry’s ability to accurately diagnose disease, identify the optimal therapies for treatment, and accurately monitor responses to those therapies.”
Prior to joining Olaris, Chaffee was most recently Chief Business Officer at Affinivax, Inc., until its sale to GlaxoSmithKline in May of 2022. Prior to his time at Affinivax, Chaffee was Chief Business Officer and Chief Financial Officer at Praxis Precision Medicines, a clinical-stage genetic neuroscience company, where he raised over $100 million in private equity to fund an innovative pipeline identifying candidates for the development of novel therapies for patients affected by central nervous system disorders. He also served as Entrepreneur in Residence with Atlas Venture, where he co-founded and served as Head of Business Operations at Kymera Therapeutics, a biopharmaceutical company, started from the concept of using the body’s innate protein degradation machinery to target previously untreatable diseases. In addition to early-stage company building, Stuart has spent time at Amgen in drug discovery and at Biogen in several corporate functions. He received his B.S. in Chemistry from the College of William and Mary, a Ph.D. in Synthetic Organic Chemistry from Yale University, and an MBA in Finance from the Wharton School at the University of Pennsylvania.
“We are honored to welcome Stuart to our leadership team. As we continue to advance our myOLARIS products, his financial, strategic and operations expertise will be critical accelerators during this next stage of growth,” said Dr. Elizabeth O’Day, Chief Executive Officer and Founder. ”I am excited to work together to develop diagnostics that transform how we think about disease diagnosis and treatment.”
About Olaris
Olaris is working to fundamentally change how diseases are treated by leveraging our proprietary metabolomics and machine learning platform to identify metabolomics-based biomarker signatures. Olaris develops in vitro diagnostics (IVDs) to empower patients, providers, and biopharma to pursue the most effective treatment. To learn more, visit https://myolaris.com.
Share article on social media or email:
[ad_2]